# Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

> **NCT07443397** · PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 134 (estimated)

## Conditions studied

- Whole-Brain Radiotherapy

## Interventions

- **DRUG:** Anlotinib
- **RADIATION:** Whole-brain Radiotherapy

## Key facts

- **NCT ID:** NCT07443397
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-29
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07443397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07443397, "Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07443397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*